BCL2 and inflammatory bowel disease: In an inflammatory bowel disease (IBD) model, where the accumulation of senescent cells leads to the release of SASP factors that propagate inflammation, fisetin treatment inhibits expressions of p53, p16, Bcl2, Cxcl1, Mcp1, and miRNAs related to senescence and inflammation.